Revolution medicines to deliver multiple presentations at the 2024 aacr-nci-eortc symposium and host investor webcast

Pancreatic ductal adenocarcinoma (pdac) data from rmc-6236 (ras(on) multi-selective inhibitor) and rmc-9805 (ras (on) g12d-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations pancreatic ductal adenocarcinoma (pdac) data from rmc-6236 (ras(on) multi-selective inhibitor) and rmc-9805 (ras (on) g12d-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations
NCI Ratings Summary
NCI Quant Ranking